Cellectis In Sale Talks With Pfizer : Report

(RTTNews) - The French biotech company Cellectis (CLLS) is in talks about its potential sale with Pfizer (PFE) of the US believed to be among the buyers, the Financial Times reported citing people familiar with matter.

The report indicated Cellectis was in negotiations over a deal but warned that no outcome was certain. One person said Pfizer had informally approached the company about a deal that could value the target at as much as 1.5 billion euros.

It is unclear if other parties were also in the sale talks with Cellectis, the report said.

CLLS closed Thursday's regular trading at $47.66, up $6.67 or 16.27%. In after-hours, the share further gained $0.29 or 0.61%.